We have been preparing libraries for Illumina GA and we have some problems with RNA-seq libraries. The issue that we are having is that we are seeing two peaks in bioanalyzer data (attached ppt). We are seeing this in all our RNA seq samples - no matter what organism used. We are using Illumina RNAseq kit. have anyone seen something like this? I would really appreciate any advice.
-
-
I've seen this with ChIP-Seq libraries. I think the double peak is due to library PCR dimers forming. This is similar to primer-dimers but forms from PCR products dimerizing.
You see this more often if you use high cycle numbers in your amplification. -
This happens in about a third of my RNA-Seq library preps. Try using the ultrapure T4 ligase from Enzymatics and titrating the amount of primers in the final step, going down by 0.1ul amounts from 1ul.Comment
-
two rounds DSN normalization
hello
has anyone tried to do two rounds of DSN normalization (specifically for RNA-seq)? If so, how did you do it and how did it go? Thanks.Comment
-
I have done just one round of DSN normalization using Illumina's DSN normalization kit. The protocol of which can be found at http://qb3.berkeley.edu/gsl/Protocol...OT_RELEASE.pdfOriginally posted by zorph View PostComment
-
We are also seeing double peaks in our RNA-seq library preps, even though all samples have been gel extracted at 350bp. Does anyone know how it is possible to still have 700 bp fragments after gel extraction and what we can do to remove the longer fragments? Thanks.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment